{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:20:29Z","timestamp":1793319629889,"version":"4.5.0"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40265-025-02237-2","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T07:34:02Z","timestamp":1761377642000},"page":"1585-1608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Can Gene Therapy Transform the Treatment Landscape of Posterior Segment Eye Diseases? A Comprehensive Review of Recent Advancements"],"prefix":"10.1007","volume":"85","author":[{"given":"Kai-Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Chun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ming","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"2237_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40662-016-0063-5","volume":"3","author":"KL Pennington","year":"2016","unstructured":"Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond). 2016;3:34. https:\/\/doi.org\/10.1186\/s40662-016-0063-5.","journal-title":"Eye Vis (Lond)"},{"issue":"2","key":"2237_CR2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/s2214-109x(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u201316. https:\/\/doi.org\/10.1016\/s2214-109x(13)70145-1.","journal-title":"Lancet Glob Health"},{"issue":"11","key":"2237_CR3","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580\u201391. https:\/\/doi.org\/10.1016\/j.ophtha.2021.04.027.","journal-title":"Ophthalmology"},{"key":"2237_CR4","unstructured":"Fahim AT, Daiger SP, Weleber RG. Nonsyndromic retinitis pigmentosa overview. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(\u00ae). Seattle (WA): University of Washington, Seattle. Copyright \u00a9 1993-2025, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. 1993."},{"issue":"12","key":"2237_CR5","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1001\/jamaophthalmol.2022.4401","volume":"140","author":"DB Rein","year":"2022","unstructured":"Rein DB, et al. Prevalence of age-related macular degeneration in the US in 2019. JAMA Ophthalmol. 2022;140(12):1202\u20138. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.4401.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"2237_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193\u2013201. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.011.","journal-title":"Ophthalmology"},{"issue":"2","key":"2237_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/hum.2006.17.167","volume":"17","author":"PA Campochiaro","year":"2006","unstructured":"Campochiaro PA, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther. 2006;17(2):167\u201376. https:\/\/doi.org\/10.1089\/hum.2006.17.167.","journal-title":"Hum Gene Ther"},{"issue":"10097","key":"2237_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/s0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849\u201360. https:\/\/doi.org\/10.1016\/s0140-6736(17)31868-8.","journal-title":"Lancet"},{"key":"2237_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ddtec.2018.05.001","volume":"28","author":"CL Xu","year":"2018","unstructured":"Xu CL, Park KS, Tsang SH. CRISPR\/Cas9 genome surgery for retinal diseases. Drug Discov Today Technol. 2018;28:23\u201332. https:\/\/doi.org\/10.1016\/j.ddtec.2018.05.001.","journal-title":"Drug Discov Today Technol"},{"issue":"9","key":"2237_CR10","doi-asserted-by":"publisher","first-page":"a017285","DOI":"10.1101\/cshperspect.a017285","volume":"5","author":"EA Pierce","year":"2015","unstructured":"Pierce EA, Bennett J. The status of RPE65 gene therapy trials: safety and efficacy. Cold Spring Harb Perspect Med. 2015;5(9):a017285. https:\/\/doi.org\/10.1101\/cshperspect.a017285.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"2237_CR11","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00417-021-05508-2","volume":"260","author":"C Deng","year":"2022","unstructured":"Deng C, et al. Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis. Graefes Arch Clin Exp Ophthalmol. 2022;260(5):1543\u201350. https:\/\/doi.org\/10.1007\/s00417-021-05508-2.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"2237_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ymthe.2019.08.013","volume":"28","author":"KL Gardiner","year":"2020","unstructured":"Gardiner KL, et al. Long-term structural outcomes of late-stage RPE65 gene therapy. Mol Ther. 2020;28(1):266\u201378. https:\/\/doi.org\/10.1016\/j.ymthe.2019.08.013.","journal-title":"Mol Ther"},{"key":"2237_CR13","unstructured":"ROCKVILLE, REGENXBIO announces additional positive long-term and interim phase I\/IIa trial update for RGX-314 for the treatment of wet AMD, ed, 2020."},{"issue":"10436","key":"2237_CR14","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/s0140-6736(24)00310-6","volume":"403","author":"PA Campochiaro","year":"2024","unstructured":"Campochiaro PA, et al. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study. Lancet. 2024;403(10436):1563\u201373. https:\/\/doi.org\/10.1016\/s0140-6736(24)00310-6.","journal-title":"Lancet"},{"issue":"1","key":"2237_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.18553\/jmcp.2025.31.1.88","volume":"31","author":"V Saundankar","year":"2025","unstructured":"Saundankar V, et al. Annual prevalence of geographic atrophy and wet age-related macular degeneration among Medicare Advantage enrollees in a US health plan. J Manag Care Spec Pharm. 2025;31(1):88\u201394. https:\/\/doi.org\/10.18553\/jmcp.2025.31.1.88.","journal-title":"J Manag Care Spec Pharm"},{"key":"2237_CR16","unstructured":"Macular degeneration facts & figures, ed, 2024."},{"issue":"14","key":"2237_CR17","doi-asserted-by":"publisher","first-page":"5614","DOI":"10.18632\/aging.204187","volume":"14","author":"H Chung","year":"2022","unstructured":"Chung H, Kim C. Nutlin-3a for age-related macular degeneration. Aging (Albany NY). 2022;14(14):5614\u20136. https:\/\/doi.org\/10.18632\/aging.204187.","journal-title":"Aging (Albany NY)"},{"key":"2237_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1146\/annurev-genom-090413-025610","volume":"15","author":"LG Fritsche","year":"2014","unstructured":"Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A. Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet. 2014;15:151\u201371. https:\/\/doi.org\/10.1146\/annurev-genom-090413-025610.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"3","key":"2237_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ophtha.2018.08.006","volume":"126","author":"BMJ Merle","year":"2019","unstructured":"Merle BMJ, et al. Mediterranean diet and incidence of advanced age-related macular degeneration: the EYE-RISK Consortium. Ophthalmology. 2019;126(3):381\u201390. https:\/\/doi.org\/10.1016\/j.ophtha.2018.08.006.","journal-title":"Ophthalmology"},{"key":"2237_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100858","volume":"79","author":"K Kaarniranta","year":"2020","unstructured":"Kaarniranta K, et al. Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration. Prog Retin Eye Res. 2020;79:100858. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100858.","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"2237_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41433-021-01842-1","volume":"36","author":"AM Khanani","year":"2022","unstructured":"Khanani AM, et al. Review of gene therapies for age-related macular degeneration. Eye (Lond). 2022;36(2):303\u201311. https:\/\/doi.org\/10.1038\/s41433-021-01842-1.","journal-title":"Eye (Lond)"},{"key":"2237_CR22","doi-asserted-by":"publisher","first-page":"1377098","DOI":"10.3389\/fopht.2024.1377098","volume":"4","author":"JS Bellingrath","year":"2024","unstructured":"Bellingrath JS, Li KV, Aziz K, Izzi JM, Liu YV, Singh MS. Large animal model species in pluripotent stem cell therapy research and development for retinal diseases: a systematic review. Front Ophthalmol (Lausanne). 2024;4:1377098. https:\/\/doi.org\/10.3389\/fopht.2024.1377098.","journal-title":"Front Ophthalmol (Lausanne)"},{"issue":"8","key":"2237_CR23","first-page":"352","volume":"62","author":"B Busbee","year":"2021","unstructured":"Busbee B, et al. Phase 1 study of intravitreal gene therapy with ADVM-022 for neovascular AMD (OPTIC trial). Investig Ophthalmol Vis Sci. 2021;62(8):352\u2013352.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"1","key":"2237_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41433-020-0844-x","volume":"35","author":"DH Steel","year":"2021","unstructured":"Steel DH, Donachie PHJ, Aylward GW, Laidlaw DA, Williamson TH, Yorston D. Factors affecting anatomical and visual outcome after macular hole surgery: findings from a large prospective UK cohort. Eye (Lond). 2021;35(1):316\u201325. https:\/\/doi.org\/10.1038\/s41433-020-0844-x.","journal-title":"Eye (Lond)"},{"issue":"1","key":"2237_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000355077","volume":"51","author":"F Kuhn","year":"2014","unstructured":"Kuhn F, Aylward B. Rhegmatogenous retinal detachment: a reappraisal of its pathophysiology and treatment. Ophthalmic Res. 2014;51(1):15\u201331. https:\/\/doi.org\/10.1159\/000355077.","journal-title":"Ophthalmic Res"},{"issue":"3","key":"2237_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/ceo.13914","volume":"49","author":"AT Fung","year":"2021","unstructured":"Fung AT, Galvin J, Tran T. Epiretinal membrane: a review. Clin Exp Ophthalmol. 2021;49(3):289\u2013308. https:\/\/doi.org\/10.1111\/ceo.13914.","journal-title":"Clin Exp Ophthalmol"},{"key":"2237_CR27","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.2147\/opth.S143898","volume":"11","author":"M Bond-Taylor","year":"2017","unstructured":"Bond-Taylor M, Jakobsson G, Zetterberg M. Posterior vitreous detachment - prevalence of and risk factors for retinal tears. Clin Ophthalmol. 2017;11:1689\u201395. https:\/\/doi.org\/10.2147\/opth.S143898.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"2237_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/0301-4738.178155","volume":"64","author":"A Das","year":"2016","unstructured":"Das A. Diabetic retinopathy: battling the global epidemic. Indian J Ophthalmol. 2016;64(1):2\u20133. https:\/\/doi.org\/10.4103\/0301-4738.178155.","journal-title":"Indian J Ophthalmol"},{"issue":"8","key":"2237_CR29","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamaophthalmol.2023.2289","volume":"141","author":"EA Lundeen","year":"2023","unstructured":"Lundeen EA, et al. Prevalence of diabetic retinopathy in the US in 2021. JAMA Ophthalmol. 2023;141(8):747\u201354. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2289.","journal-title":"JAMA Ophthalmol"},{"key":"2237_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14202340","author":"Z Zlatarova","year":"2024","unstructured":"Zlatarova Z, et al. Prevalence of diabetic retinopathy among diabetic patients from northeastern Bulgaria. Diagnostics (Basel). 2024. https:\/\/doi.org\/10.3390\/diagnostics14202340.","journal-title":"Diagnostics (Basel)."},{"issue":"6","key":"2237_CR31","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2016.02.022.","journal-title":"Ophthalmology"},{"issue":"7","key":"2237_CR32","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","volume":"127","author":"QD Nguyen","year":"2020","unstructured":"Nguyen QD, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127(7):963\u201376. https:\/\/doi.org\/10.1016\/j.ophtha.2019.12.031.","journal-title":"Ophthalmology"},{"issue":"1","key":"2237_CR33","doi-asserted-by":"publisher","first-page":"P71","DOI":"10.1016\/j.ophtha.2020.10.022","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern\u00ae. Ophthalmology. 2021;128(1):P71-p150. https:\/\/doi.org\/10.1016\/j.ophtha.2020.10.022.","journal-title":"Ophthalmology"},{"key":"2237_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.651639","volume":"12","author":"R Hage","year":"2021","unstructured":"Hage R, Vignal-Clermont C. Leber hereditary optic neuropathy: review of treatment and management. Front Neurol. 2021;12:651639. https:\/\/doi.org\/10.3389\/fneur.2021.651639.","journal-title":"Front Neurol"},{"key":"2237_CR35","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/21678707.2018.1508340","volume":"6","author":"SR Russell","year":"2018","unstructured":"Russell SR, Bennett J, Maguire AM, High KA. Voretigene neparvovec-rzyl for the treatment of biallelic RPE65 mutation\u2013associated retinal dystrophy. Expert Opin Orphan Drugs. 2018;6:457\u201364.","journal-title":"Expert Opin Orphan Drugs"},{"key":"2237_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054408","author":"V Kaushik","year":"2023","unstructured":"Kaushik V, Gessa L, Kumar N, Fernandes H. Towards a new biomarker for diabetic retinopathy: exploring RBP3 structure and retinoids binding for functional imaging of eyes in vivo. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24054408.","journal-title":"Int J Mol Sci"},{"key":"2237_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.exer.2015.06.007","volume":"138","author":"RD Megaw","year":"2015","unstructured":"Megaw RD, Soares DC, Wright AF. RPGR: its role in photoreceptor physiology, human disease, and future therapies. Exp Eye Res. 2015;138:32\u201341. https:\/\/doi.org\/10.1016\/j.exer.2015.06.007. ((in Eng)).","journal-title":"Exp Eye Res"},{"issue":"2","key":"2237_CR38","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1167\/iovs.04-1065","volume":"46","author":"DH Hong","year":"2005","unstructured":"Hong DH, Pawlyk BS, Adamian M, Sandberg MA, Li T. A single, abbreviated RPGR-ORF15 variant reconstitutes RPGR function in vivo. Invest Ophthalmol Vis Sci. 2005;46(2):435\u201341. https:\/\/doi.org\/10.1167\/iovs.04-1065.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2237_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100861","volume":"79","author":"FPM Cremers","year":"2020","unstructured":"Cremers FPM, Lee W, Collin RWJ, Allikmets R. Clinical spectrum, genetic complexity and therapeutic approaches for retinal disease caused by ABCA4 mutations. Prog Retin Eye Res. 2020;79:100861. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100861.","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"2237_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.preteyeres.2011.12.001","volume":"31","author":"JR Sparrow","year":"2012","unstructured":"Sparrow JR, et al. The bisretinoids of retinal pigment epithelium. Prog Retin Eye Res. 2012;31(2):121\u201335. https:\/\/doi.org\/10.1016\/j.preteyeres.2011.12.001.","journal-title":"Prog Retin Eye Res"},{"key":"2237_CR41","doi-asserted-by":"publisher","unstructured":"Landowski M, Kelly U, Klingeborn M, Groelle M, Ding JD, Grigsby D, Bowes Rickman C. Human complement factor H Y402H polymorphism causes an age-related macular degeneration phenotype and lipoprotein dysregulation in mice. Proc Natl Acad Sci U S A. 2019;116(9):3703\u201311. https:\/\/doi.org\/10.1073\/pnas.1814014116. Epub 2019 Feb 11. PMID: 30808757; PMCID: PMC6397537","DOI":"10.1073\/pnas.1814014116"},{"key":"2237_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2021.108605","volume":"210","author":"A May","year":"2021","unstructured":"May A, et al. Ongoing controversies and recent insights of the ARMS2-HTRA1 locus in age-related macular degeneration. Exp Eye Res. 2021;210:108605. https:\/\/doi.org\/10.1016\/j.exer.2021.108605.","journal-title":"Exp Eye Res"},{"issue":"2","key":"2237_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrg3118","volume":"13","author":"G Gibson","year":"2012","unstructured":"Gibson G. Rare and common variants: twenty arguments. Nat Rev Genet. 2012;13(2):135\u201345. https:\/\/doi.org\/10.1038\/nrg3118.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"2237_CR44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13073-015-0138-2","volume":"7","author":"PL Auer","year":"2015","unstructured":"Auer PL, Lettre G. Rare variant association studies: considerations, challenges and opportunities. Genome Med. 2015;7(1):16. https:\/\/doi.org\/10.1186\/s13073-015-0138-2.","journal-title":"Genome Med"},{"key":"2237_CR45","unstructured":"Fletcher L. Common and rare variation both contribute to the onset of retinal disease, ed. 2023."},{"issue":"2","key":"2237_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1010587","volume":"19","author":"H Currant","year":"2023","unstructured":"Currant H, et al. Sub-cellular level resolution of common genetic variation in the photoreceptor layer identifies continuum between rare disease and common variation. PLoS Genet. 2023;19(2):e1010587. https:\/\/doi.org\/10.1371\/journal.pgen.1010587.","journal-title":"PLoS Genet"},{"issue":"10","key":"2237_CR47","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1007\/s00018-021-03796-9","volume":"78","author":"A Armento","year":"2021","unstructured":"Armento A, Ueffing M, Clark SJ. The complement system in age-related macular degeneration. Cell Mol Life Sci. 2021;78(10):4487\u2013505. https:\/\/doi.org\/10.1007\/s00018-021-03796-9.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"2237_CR48","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.tips.2021.10.012","volume":"43","author":"AE Modell","year":"2022","unstructured":"Modell AE, Lim D, Nguyen TM, Sreekanth V, Choudhary A. Crispr-based therapeutics: current challenges and future applications. Trends Pharmacol Sci. 2022;43(2):151\u201361. https:\/\/doi.org\/10.1016\/j.tips.2021.10.012.","journal-title":"Trends Pharmacol Sci"},{"issue":"36","key":"2237_CR49","doi-asserted-by":"publisher","first-page":"E3425","DOI":"10.1073\/pnas.1217091110","volume":"110","author":"X Xin","year":"2013","unstructured":"Xin X, et al. Hypoxic retinal Muller cells promote vascular permeability by HIF-1-dependent up-regulation of angiopoietin-like 4. Proc Natl Acad Sci USA. 2013;110(36):E3425\u201334. https:\/\/doi.org\/10.1073\/pnas.1217091110.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2237_CR50","first-page":"764","volume":"41","author":"ME Pease","year":"2000","unstructured":"Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Investig Ophthalmol Vis Sci. 2000;41(3):764\u201374.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"no. 3","key":"2237_CR51","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2174\/1566523217666171116170040","volume":"17","author":"C Campa","year":"2017","unstructured":"Campa C, Gallenga CE, Bolletta E, Perri P. The role of gene therapy in the treatment of retinal diseases: a review. Curr Gene Ther. 2017;17(3):194\u2013213. https:\/\/doi.org\/10.2174\/1566523217666171116170040.","journal-title":"Curr Gene Ther"},{"issue":"4","key":"2237_CR52","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/2474126418783934","volume":"2","author":"S Sun","year":"2018","unstructured":"Sun S, Montezuma SR. Gene therapy for inherited retinopathies: update on development progress. J VitreoRetin Dis. 2018;2(4):219\u201326. https:\/\/doi.org\/10.1177\/2474126418783934.","journal-title":"J VitreoRetin Dis"},{"issue":"4","key":"2237_CR53","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1080\/08164622.2021.1880863","volume":"104","author":"ML Hu","year":"2021","unstructured":"Hu ML, et al. Gene therapy for inherited retinal diseases: progress and possibilities. Clin Exp Optom. 2021;104(4):444\u201354. https:\/\/doi.org\/10.1080\/08164622.2021.1880863.","journal-title":"Clin Exp Optom"},{"issue":"39","key":"2237_CR54","doi-asserted-by":"publisher","first-page":"e2210104119","DOI":"10.1073\/pnas.2210104119","volume":"119","author":"S Suh","year":"2022","unstructured":"Suh S, Choi EH, Raguram A, Liu DR, Palczewski K. Precision genome editing in the eye. Proc Natl Acad Sci USA. 2022;119(39):e2210104119. https:\/\/doi.org\/10.1073\/pnas.2210104119.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2237_CR55","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.preteyeres.2010.04.002","volume":"29","author":"AV Cideciyan","year":"2010","unstructured":"Cideciyan AV. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res. 2010;29(5):398\u2013427. https:\/\/doi.org\/10.1016\/j.preteyeres.2010.04.002.","journal-title":"Prog Retin Eye Res"},{"key":"2237_CR56","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/B978-0-12-816222-4.00017-4","volume-title":"Genetics and genomics of eye disease","author":"PPA Dhooge","year":"2020","unstructured":"Dhooge PPA, Valkenburg D, Hoyng CB. Chapter 16\u2014gene therapy for inherited retinal diseases. In: Gao XR, editor. Genetics and genomics of eye disease. Cambridge: Academic Press; 2020. p. 279\u201395."},{"issue":"9923","key":"2237_CR57","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","volume":"383","author":"RE MacLaren","year":"2014","unstructured":"MacLaren RE, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial. Lancet. 2014;383(9923):1129\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(13)62117-0.","journal-title":"Lancet"},{"issue":"1","key":"2237_CR58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3892\/etm.2021.10948","volume":"23","author":"AD Moraru","year":"2022","unstructured":"Moraru AD, Costin D, Iorga RE, Munteanu M, Moraru RL, Branisteanu DC. Current trends in gene therapy for retinal diseases (Review). Exp Ther Med. 2022;23(1):26. https:\/\/doi.org\/10.3892\/etm.2021.10948.","journal-title":"Exp Ther Med"},{"key":"2237_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.visres.2023.108192","volume":"206","author":"AL Yan","year":"2023","unstructured":"Yan AL, Du SW, Palczewski K. Genome editing, a superior therapy for inherited retinal diseases. Vis Res. 2023;206:108192. https:\/\/doi.org\/10.1016\/j.visres.2023.108192. ((in Eng)).","journal-title":"Vis Res"},{"key":"2237_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/cells12030440","author":"S Hansen","year":"2023","unstructured":"Hansen S, McClements ME, Corydon TJ, MacLaren RE. Future perspectives of prime editing for the treatment of inherited retinal diseases. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12030440.","journal-title":"Cells"},{"key":"2237_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2023.1270561","volume":"3","author":"C Carvalho","year":"2023","unstructured":"Carvalho C, Lemos L, Antas P, Seabra MC. Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnology. Front Ophthalmol. 2023;3:1270561. https:\/\/doi.org\/10.3389\/fopht.2023.1270561. ((in Eng)).","journal-title":"Front Ophthalmol"},{"issue":"3","key":"2237_CR62","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/crispr.2021.0141","volume":"5","author":"J Pulman","year":"2022","unstructured":"Pulman J, Sahel JA, Dalkara D. New editing tools for gene therapy in inherited retinal dystrophies. CRISPR J. 2022;5(3):377\u201388. https:\/\/doi.org\/10.1089\/crispr.2021.0141.","journal-title":"CRISPR J"},{"issue":"8","key":"2237_CR63","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1007\/s12015-023-10585-3","volume":"19","author":"M Lotfi","year":"2023","unstructured":"Lotfi M, et al. Recent advances in CRISPR\/Cas9 delivery approaches for therapeutic gene editing of stem cells. Stem Cell Rev Rep. 2023;19(8):2576\u201396. https:\/\/doi.org\/10.1007\/s12015-023-10585-3.","journal-title":"Stem Cell Rev Rep"},{"issue":"7","key":"2237_CR64","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14304\/surya.jpr.v4n7.5","volume":"4","author":"J Chery","year":"2016","unstructured":"Chery J. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J. 2016;4(7):35\u201350. https:\/\/doi.org\/10.14304\/surya.jpr.v4n7.5.","journal-title":"Postdoc J"},{"key":"2237_CR65","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-3-030-27378-1_14","volume":"1185","author":"SM Moore","year":"2019","unstructured":"Moore SM, Skowronska-Krawczyk D, Chao DL. Emerging concepts for RNA therapeutics for inherited retinal disease. Adv Exp Med Biol. 2019;1185:85\u20139. https:\/\/doi.org\/10.1007\/978-3-030-27378-1_14.","journal-title":"Adv Exp Med Biol"},{"issue":"no. 5","key":"2237_CR66","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/14712598.2021.1856365","volume":"21","author":"MC Gemayel","year":"2021","unstructured":"Gemayel MC, Bhatwadekar AD, Ciulla T. RNA therapeutics for retinal diseases. Expert Opin Biol Ther. 2021;21(5):603\u201313. https:\/\/doi.org\/10.1080\/14712598.2021.1856365.","journal-title":"Expert Opin Biol Ther"},{"key":"2237_CR67","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3389\/fphys.2018.00953","volume":"9","author":"A Laina","year":"2018","unstructured":"Laina A, Gatsiou A, Georgiopoulos G, Stamatelopoulos K, Stellos K. RNA therapeutics in cardiovascular precision medicine. Front Physiol. 2018;9:953. https:\/\/doi.org\/10.3389\/fphys.2018.00953.","journal-title":"Front Physiol"},{"issue":"no. 8","key":"2237_CR68","first-page":"697","volume":"66","author":"A-M Bleau","year":"2025","unstructured":"Bleau A-M, Jimenez AI, Gramis V, Ruz V, Segerros RA, Vargas B. Clinical trial for SYL1801, a new siRNA-based treatment for neovascular AMD. Investig Ophthalmol Vis Sci. 2025;66(8):697\u2013697.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2237_CR69","unstructured":"Sirna Therapeutics, Inc. reports final results from phase 1 study on its RNAi-based therapeutic for age-related macular degeneration, ed. 2006."},{"key":"2237_CR70","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-vision-082114-035532","volume":"1","author":"ZH Pan","year":"2015","unstructured":"Pan ZH, Lu Q, Bi A, Dizhoor AM, Abrams GW. Optogenetic approaches to restoring vision. Annu Rev Vis Sci. 2015;1:185\u2013210. https:\/\/doi.org\/10.1146\/annurev-vision-082114-035532.","journal-title":"Annu Rev Vis Sci"},{"key":"2237_CR71","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/978-981-15-8763-4_38","volume":"1293","author":"Q Lu","year":"2021","unstructured":"Lu Q, Pan ZH. Optogenetic strategies for vision restoration. Adv Exp Med Biol. 2021;1293:545\u201355. https:\/\/doi.org\/10.1007\/978-981-15-8763-4_38.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"2237_CR72","doi-asserted-by":"publisher","first-page":"374","DOI":"10.4103\/2008-322x.143379","volume":"9","author":"BS Henriksen","year":"2014","unstructured":"Henriksen BS, Marc RE, Bernstein PS. Optogenetics for retinal disorders. J Ophthalmic Vis Res. 2014;9(3):374\u201382. https:\/\/doi.org\/10.4103\/2008-322x.143379.","journal-title":"J Ophthalmic Vis Res"},{"key":"2237_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.570909","volume":"14","author":"ME McClements","year":"2020","unstructured":"McClements ME, Staurenghi F, MacLaren RE, Cehajic-Kapetanovic J. Optogenetic gene therapy for the degenerate retina: recent advances. Front Neurosci. 2020;14:570909. https:\/\/doi.org\/10.3389\/fnins.2020.570909.","journal-title":"Front Neurosci"},{"issue":"5","key":"2237_CR74","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1051\/medsci\/20153105015","volume":"31","author":"H Khabou","year":"2015","unstructured":"Khabou H, Dalkara D. [Developments in gene delivery vectors for ocular gene therapy], (in Fre). Med Sci (Paris). 2015;31(5):529\u201337. https:\/\/doi.org\/10.1051\/medsci\/20153105015.","journal-title":"Med Sci (Paris)"},{"issue":"11","key":"2237_CR75","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/gt.2008.66","volume":"15","author":"PK Buch","year":"2008","unstructured":"Buch PK, Bainbridge JW, Ali RR. AAV-mediated gene therapy for retinal disorders: from mouse to man. Gene Ther. 2008;15(11):849\u201357. https:\/\/doi.org\/10.1038\/gt.2008.66.","journal-title":"Gene Ther"},{"key":"2237_CR76","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.preteyeres.2014.08.001","volume":"43","author":"I Trapani","year":"2014","unstructured":"Trapani I, Puppo A, Auricchio A. Vector platforms for gene therapy of inherited retinopathies. Prog Retin Eye Res. 2014;43:108\u201328. https:\/\/doi.org\/10.1016\/j.preteyeres.2014.08.001.","journal-title":"Prog Retin Eye Res"},{"issue":"10","key":"2237_CR77","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3928\/23258160-20191009-01","volume":"50","author":"RM Hussain","year":"2019","unstructured":"Hussain RM, Tran KD, Maguire AM, Berrocal AM. Subretinal injection of voretigene neparvovec-rzyl in a patient with RPE65-associated Leber\u2019s congenital amaurosis. Ophthalmic Surg Lasers Imaging Retina. 2019;50(10):661\u20133. https:\/\/doi.org\/10.3928\/23258160-20191009-01.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2237_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164717","author":"C Irigoyen","year":"2022","unstructured":"Irigoyen C, Amenabar Alonso A, Sanchez-Molina J, Rodr\u00edguez-Hidalgo M, Lara-L\u00f3pez A, Ruiz-Ederra J. Subretinal injection techniques for retinal disease: a review. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11164717.","journal-title":"J Clin Med"},{"issue":"3","key":"2237_CR79","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2174\/1566523217666171003170348","volume":"17","author":"G Kalesnykas","year":"2017","unstructured":"Kalesnykas G, et al. Comparative study of adeno-associated virus, adenovirus, bacu lovirus and lentivirus vectors for gene therapy of the eyes. Curr Gene Ther. 2017;17(3):235\u201347. https:\/\/doi.org\/10.2174\/1566523217666171003170348.","journal-title":"Curr Gene Ther"},{"issue":"29","key":"2237_CR80","doi-asserted-by":"publisher","first-page":"7158","DOI":"10.1016\/j.biomaterials.2013.06.002","volume":"34","author":"A Koirala","year":"2013","unstructured":"Koirala A, Conley SM, Naash MI. A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium. Biomaterials. 2013;34(29):7158\u201367. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.06.002.","journal-title":"Biomaterials"},{"issue":"3","key":"2237_CR81","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.visres.2007.07.012","volume":"48","author":"X Cai","year":"2008","unstructured":"Cai X, Conley S, Naash M. Nanoparticle applications in ocular gene therapy. Vis Res. 2008;48(3):319\u201324. https:\/\/doi.org\/10.1016\/j.visres.2007.07.012.","journal-title":"Vis Res"},{"issue":"1","key":"2237_CR82","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ymthe.2019.09.010","volume":"28","author":"D Sun","year":"2020","unstructured":"Sun D, et al. Non-viral gene therapy for Stargardt disease with ECO\/pRHO-ABCA4 self-assembled nanoparticles. Mol Ther. 2020;28(1):293\u2013303. https:\/\/doi.org\/10.1016\/j.ymthe.2019.09.010.","journal-title":"Mol Ther"},{"issue":"18","key":"2237_CR83","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/sj.gt.3302337","volume":"11","author":"DJ Wells","year":"2004","unstructured":"Wells DJ. Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther. 2004;11(18):1363\u20139. https:\/\/doi.org\/10.1038\/sj.gt.3302337.","journal-title":"Gene Ther"},{"issue":"8","key":"2237_CR84","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.drudis.2019.05.038","volume":"24","author":"T Bordet","year":"2019","unstructured":"Bordet T, Behar-Cohen F. Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives. Drug Discov Today. 2019;24(8):1685\u201393. https:\/\/doi.org\/10.1016\/j.drudis.2019.05.038.","journal-title":"Drug Discov Today"},{"issue":"4","key":"2237_CR85","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000479157","volume":"58","author":"Y Peng","year":"2017","unstructured":"Peng Y, Tang L, Zhou Y. Subretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases. Ophthalmic Res. 2017;58(4):217\u201326. https:\/\/doi.org\/10.1159\/000479157.","journal-title":"Ophthalmic Res"},{"issue":"9","key":"2237_CR86","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.4103\/1673-5374.306063","volume":"16","author":"M Ross","year":"2021","unstructured":"Ross M, Ofri R. The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery. Neural Regen Res. 2021;16(9):1751\u20139. https:\/\/doi.org\/10.4103\/1673-5374.306063.","journal-title":"Neural Regen Res"},{"issue":"13","key":"2237_CR87","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1167\/iovs.17-22473","volume":"58","author":"IP Seitz","year":"2017","unstructured":"Seitz IP, et al. Superior retinal gene transfer and biodistribution profile of subretinal versus intravitreal delivery of AAV8 in nonhuman primates. Investig Ophthalmol Vis Sci. 2017;58(13):5792\u2013801. https:\/\/doi.org\/10.1167\/iovs.17-22473.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"9","key":"2237_CR88","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1080\/14712598.2022.2121646","volume":"22","author":"KD Kovacs","year":"2022","unstructured":"Kovacs KD, Ciulla TA, Kiss S. Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniques. Expert Opin Biol Ther. 2022;22(9):1193\u2013208. https:\/\/doi.org\/10.1080\/14712598.2022.2121646.","journal-title":"Expert Opin Biol Ther"},{"key":"2237_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/ph16091241","author":"KY Wu","year":"2023","unstructured":"Wu KY, Fujioka JK, Gholamian T, Zaharia M, Tran SD. Suprachoroidal injection: a novel approach for targeted drug delivery. Pharmaceuticals (Basel). 2023. https:\/\/doi.org\/10.3390\/ph16091241.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"2237_CR90","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/jop.2019.0126","volume":"36","author":"V Kansara","year":"2020","unstructured":"Kansara V, Muya L, Wan CR, Ciulla TA. Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases. J Ocul Pharmacol Ther. 2020;36(6):384\u201392. https:\/\/doi.org\/10.1089\/jop.2019.0126.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"2237_CR91","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/tvst.10.4.3","volume":"10","author":"YK Chan","year":"2021","unstructured":"Chan YK, et al. Inflammation in viral vector-mediated ocular gene therapy: a review and report from a workshop hosted by the foundation fighting blindness, 9\/2020. Transl Vis Sci Technol. 2021;10(4):3\u20133.","journal-title":"Transl Vis Sci Technol"},{"issue":"12","key":"2237_CR92","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.3390\/cells11121881","volume":"11","author":"M Gehrke","year":"2022","unstructured":"Gehrke M, Diedrichs-M\u00f6hring M, Bogedein J, B\u00fcning H, Michalakis S, Wildner G. Immunogenicity of novel AAV capsids for retinal gene therapy. Cells. 2022;11(12):1881.","journal-title":"Cells"},{"issue":"4","key":"2237_CR93","doi-asserted-by":"publisher","first-page":"491","DOI":"10.59249\/HWID7537","volume":"97","author":"L Banou","year":"2024","unstructured":"Banou L, Sarrafpour S, Teng CC, Liu J. Ocular gene therapy: an overview of viral vectors, immune responses, and future directions. Yale J Biol Med. 2024;97(4):491.","journal-title":"Yale J Biol Med"},{"issue":"7","key":"2237_CR94","first-page":"4903","volume":"65","author":"R Bhandari","year":"2024","unstructured":"Bhandari R. Subretinal delivery of investigational ABBV-RGX-314 for neovascular age-related macular degeneration (nAMD): a phase II pharmacodynamic study. Investig Ophthalmol Vis Sci. 2024;65(7):4903\u20134903.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2237_CR95","unstructured":"REGENXBID, REGENXBIO announces positive interim data from phase II AAVIATE\u00ae trial of ABBV-RGX-314 for the treatment of wet AMD using suprachoroidal delivery, ed. 2024."},{"issue":"3","key":"2237_CR96","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1089\/jop.2021.0001","volume":"37","author":"CM Gelfman","year":"2021","unstructured":"Gelfman CM, et al. Comprehensive preclinical assessment of ADVM-022, an intravitreal anti-VEGF gene therapy for the treatment of neovascular AMD and diabetic macular edema. J Ocul Pharmacol Ther. 2021;37(3):181\u201390. https:\/\/doi.org\/10.1089\/jop.2021.0001.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"2237_CR97","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ymthe.2018.11.003","volume":"27","author":"R Grishanin","year":"2019","unstructured":"Grishanin R, et al. Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration. Mol Ther. 2019;27(1):118\u201329. https:\/\/doi.org\/10.1016\/j.ymthe.2018.11.003.","journal-title":"Mol Ther"},{"issue":"4","key":"2237_CR98","first-page":"102","volume":"29","author":"S Kiss","year":"2021","unstructured":"Kiss S, Roller CH, Turpcu A, Chung C, Osborne A. ADVM-022 intravitreal gene therapy for neovascular AMD-results from the phase 1 OPTIC study. Mol Ther. 2021;29(4):102\u2013102.","journal-title":"Mol Ther"},{"key":"2237_CR99","first-page":"40","volume":"17","author":"S Kiss","year":"2020","unstructured":"Kiss S. Vector considerations for ocular gene therapy. Retin Physician. 2020;17:40\u20135.","journal-title":"Retin Physician"},{"key":"2237_CR100","unstructured":"4DMT announces accelerated 4D-150 phase 3 development in wet AMD and streamlined organization to drive late-stage execution, ed: 4DMT. 2025."},{"key":"2237_CR101","unstructured":"Harp MD. 4DMT enrolls first patient in phase 3 4FRONT-1 evaluating 4D-150 for the treatment of wet AMD, ed. 2024."},{"key":"2237_CR102","first-page":"36","volume":"17","author":"F Siddiqui","year":"2020","unstructured":"Siddiqui F, Aziz A, Khanani A. Gene therapy for neovascular AMD. Retin Physician. 2020;17:36\u20139.","journal-title":"Retin Physician"},{"key":"2237_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13020288","author":"CR Wan","year":"2021","unstructured":"Wan CR, Muya L, Kansara V, Ciulla TA. Suprachoroidal delivery of small molecules, nanoparticles, gene and cell therapies for ocular diseases. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13020288.","journal-title":"Pharmaceutics"},{"key":"2237_CR104","unstructured":"Newswire P. REGENXBIO announces additional positive interim phase I\/IIa and long-term follow-up data of RGX-314 for the treatment of wet AMD."},{"key":"2237_CR105","unstructured":"C. Trials.gov. Pivotal 1 study of ABBV-RGX-314 (also known as RGX-314) gene therapy administered via subretinal delivery one time in participants with nAMD (ATMOSPHERE)."},{"key":"2237_CR106","unstructured":"Cohen JK. 4D molecular therapeutics to start phase III trial for retinal disorder gene therapy in Q1 2025, ed: Precision Medicine Online, 2024."},{"key":"2237_CR107","doi-asserted-by":"publisher","first-page":"519","DOI":"10.12688\/f1000research.10998.1","volume":"6","author":"S Bahadorani","year":"2017","unstructured":"Bahadorani S, Singer M. Recent advances in the management and understanding of macular degeneration. F1000Research. 2017;6:519.","journal-title":"F1000Research"},{"issue":"31","key":"2237_CR108","doi-asserted-by":"publisher","first-page":"8789","DOI":"10.1073\/pnas.1523061113","volume":"113","author":"LX Tan","year":"2016","unstructured":"Tan LX, Toops KA, Lakkaraju A. Protective responses to sublytic complement in the retinal pigment epithelium. Proc Natl Acad Sci USA. 2016;113(31):8789\u201394.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2237_CR109","unstructured":"Ocugen clinical trial could lead to breakthrough one-time treatment for advanced dry macular degeneration, ed, 2019."},{"key":"2237_CR110","unstructured":"Newswire P. REGENXBIO presents positive interim data from and the expansion of phase II ALTITUDE\u00ae trial of RGX-314 for the treatment of diabetic retinopathy using suprachoroidal delivery, ed. 2023."},{"issue":"7","key":"2237_CR111","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65893","volume":"16","author":"KK Dhawale","year":"2024","unstructured":"Dhawale KK, Tidake P. Advancements in therapeutic approaches for proliferative vitreoretinopathy: a comprehensive review. Cureus. 2024;16(7):e65893. https:\/\/doi.org\/10.7759\/cureus.65893.","journal-title":"Cureus"},{"issue":"9","key":"2237_CR112","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","volume":"126","author":"AM Maguire","year":"2019","unstructured":"Maguire AM, et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology. 2019;126(9):1273\u201385. https:\/\/doi.org\/10.1016\/j.ophtha.2019.06.017.","journal-title":"Ophthalmology"},{"key":"2237_CR113","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ajo.2018.09.024","volume":"199","author":"DC Chung","year":"2019","unstructured":"Chung DC, et al. The natural history of inherited retinal dystrophy due to biallelic mutations in the RPE65 gene. Am J Ophthalmol. 2019;199:58\u201370. https:\/\/doi.org\/10.1016\/j.ajo.2018.09.024.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"2237_CR114","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","volume":"26","author":"J Cehajic-Kapetanovic","year":"2020","unstructured":"Cehajic-Kapetanovic J, et al. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat Med. 2020;26(3):354\u20139. https:\/\/doi.org\/10.1038\/s41591-020-0763-1.","journal-title":"Nat Med"},{"issue":"11","key":"2237_CR115","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jamaophthalmol.2019.3278","volume":"137","author":"MD Fischer","year":"2019","unstructured":"Fischer MD, et al. Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: a randomized clinical trial. JAMA Ophthalmol. 2019;137(11):1247\u201354. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.3278.","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"2237_CR116","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1038\/s41591-023-02520-3","volume":"29","author":"RE MacLaren","year":"2023","unstructured":"MacLaren RE, et al. Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial. Nat Med. 2023;29(10):2464\u201372.","journal-title":"Nat Med"},{"issue":"2","key":"2237_CR117","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/emmm.201302948","volume":"6","author":"I Trapani","year":"2014","unstructured":"Trapani I, et al. Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med. 2014;6(2):194\u2013211. https:\/\/doi.org\/10.1002\/emmm.201302948.","journal-title":"EMBO Mol Med"},{"key":"2237_CR118","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.preteyeres.2018.02.002","volume":"65","author":"MT Pardue","year":"2018","unstructured":"Pardue MT, Allen RS. Neuroprotective strategies for retinal disease. Prog Retin Eye Res. 2018;65:50\u201376. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.02.002.","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"2237_CR119","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/gt.2011.142","volume":"19","author":"AM Wilson","year":"2012","unstructured":"Wilson AM, Di Polo A. Gene therapy for retinal ganglion cell neuroprotection in glaucoma. Gene Ther. 2012;19(2):127\u201336. https:\/\/doi.org\/10.1038\/gt.2011.142.","journal-title":"Gene Ther"},{"issue":"2","key":"2237_CR120","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/wnan.1361","volume":"8","author":"N Nafissi","year":"2016","unstructured":"Nafissi N, Foldvari M. Neuroprotective therapies in glaucoma: I. Neurotrophic factor delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016;8(2):240\u201354. https:\/\/doi.org\/10.1002\/wnan.1361.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"2237_CR121","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.2147\/opth.S62021","volume":"9","author":"C Meyerson","year":"2015","unstructured":"Meyerson C, Van Stavern G, McClelland C. Leber hereditary optic neuropathy: current perspectives. Clin Ophthalmol. 2015;9:1165\u201376. https:\/\/doi.org\/10.2147\/opth.S62021.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"2237_CR122","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ophtha.2020.12.012","volume":"128","author":"NJ Newman","year":"2021","unstructured":"Newman NJ, et al. Efficacy and safety of intravitreal gene therapy for leber hereditary optic neuropathy treated within 6 months of disease onset. Ophthalmology. 2021;128(5):649\u201360. https:\/\/doi.org\/10.1016\/j.ophtha.2020.12.012.","journal-title":"Ophthalmology"},{"issue":"3","key":"2237_CR123","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/ceo.14493","volume":"53","author":"LS Kearns","year":"2025","unstructured":"Kearns LS, Staffieri SE, Mackey DA. Leber hereditary optic neuropathy: support, genetic prediction and accurate genetic counselling enhance family planning choices. Clin Exp Ophthalmol. 2025;53(3):292\u2013301. https:\/\/doi.org\/10.1111\/ceo.14493.","journal-title":"Clin Exp Ophthalmol"},{"key":"2237_CR124","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.preteyeres.2015.07.005","volume":"51","author":"JC Pastor","year":"2016","unstructured":"Pastor JC, Rojas J, Pastor-Idoate S, Di Lauro S, Gonzalez-Buendia L, Delgado-Tirado S. Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res. 2016;51:125\u201355. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.07.005.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"2237_CR125","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/iio.0000000000000258","volume":"59","author":"S Idrees","year":"2019","unstructured":"Idrees S, Sridhar J, Kuriyan AE. Proliferative vitreoretinopathy: a review. Int Ophthalmol Clin. 2019;59(1):221\u201340. https:\/\/doi.org\/10.1097\/iio.0000000000000258.","journal-title":"Int Ophthalmol Clin"},{"issue":"5","key":"2237_CR126","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000268022","volume":"29","author":"T Murata","year":"1997","unstructured":"Murata T, et al. Ocular gene therapy: experimental studies and clinical possibilities. Ophthalmic Res. 1997;29(5):242\u201351. https:\/\/doi.org\/10.1159\/000268022.","journal-title":"Ophthalmic Res"},{"issue":"1","key":"2237_CR127","first-page":"31","volume":"42","author":"A Kumar","year":"1994","unstructured":"Kumar A, Tewari HK, Bathwal DP, Khosla PK. Experimental inhibition of proliferative vitreoretinopathy in retinal detachment using daunorubicin. Indian J Ophthalmol. 1994;42(1):31\u20135.","journal-title":"Indian J Ophthalmol"},{"key":"2237_CR128","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ajo.2017.02.018","volume":"177","author":"IJ Constable","year":"2017","unstructured":"Constable IJ, et al. Gene therapy in neovascular age-related macular degeneration: three-year follow-up of a phase 1 randomized dose escalation trial. Am J Ophthalmol. 2017;177:150\u20138.","journal-title":"Am J Ophthalmol"},{"key":"2237_CR129","unstructured":"I. Adverum Biotechnologies, Adverum provides update on ADVM-022 and the INFINITY trial in patients with diabetic macular edema, ed. 2021."},{"issue":"1","key":"2237_CR130","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"J-H Wang","year":"2024","unstructured":"Wang J-H, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024;9(1):78. https:\/\/doi.org\/10.1038\/s41392-024-01780-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"2237_CR131","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1089\/hum.2019.132","volume":"30","author":"FM Dyka","year":"2019","unstructured":"Dyka FM, Molday LL, Chiodo VA, Molday RS, Hauswirth WW. Dual ABCA4-AAV vector treatment reduces pathogenic retinal A2E accumulation in a mouse model of autosomal recessive Stargardt disease. Hum Gene Ther. 2019;30(11):1361\u201370. https:\/\/doi.org\/10.1089\/hum.2019.132.","journal-title":"Hum Gene Ther"},{"key":"2237_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012375","author":"T Yee","year":"2022","unstructured":"Yee T, Wert KJ. Base and prime editing in the retina-from preclinical research toward human clinical trials. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232012375.","journal-title":"Int J Mol Sci"},{"issue":"23","key":"2237_CR133","doi-asserted-by":"publisher","first-page":"7385","DOI":"10.3390\/jcm13237385","volume":"13","author":"O Siontas","year":"2024","unstructured":"Siontas O, Ahn S. Challenges in AAV-based retinal gene therapies and the role of magnetic nanoparticle platforms. J Clin Med. 2024;13(23):7385.","journal-title":"J Clin Med"},{"issue":"12","key":"2237_CR134","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1128\/jvi.78.12.6381-6388.2004","volume":"78","author":"G Gao","year":"2004","unstructured":"Gao G, et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol. 2004;78(12):6381\u20138. https:\/\/doi.org\/10.1128\/jvi.78.12.6381-6388.2004.","journal-title":"J Virol"},{"issue":"3\u20134","key":"2237_CR135","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41434-019-0060-0","volume":"26","author":"X Cao","year":"2019","unstructured":"Cao X, Yung J, Mak H, Leung CKS. Factors governing the transduction efficiency of adeno-associated virus in the retinal ganglion cells following intravitreal injection. Gene Ther. 2019;26(3\u20134):109\u201320. https:\/\/doi.org\/10.1038\/s41434-019-0060-0.","journal-title":"Gene Ther"},{"issue":"88","key":"2237_CR136","doi-asserted-by":"publisher","first-page":"88ra54","DOI":"10.1126\/scitranslmed.3002103","volume":"3","author":"LH Vandenberghe","year":"2011","unstructured":"Vandenberghe LH, et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med. 2011;3(88):88ra54-88ra54.","journal-title":"Sci Transl Med"},{"issue":"5","key":"2237_CR137","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1172\/JCI34316","volume":"118","author":"M Allocca","year":"2008","unstructured":"Allocca M, et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Investig. 2008;118(5):1955\u201364.","journal-title":"J Clin Investig"},{"issue":"4","key":"2237_CR138","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/jgm.1126","volume":"10","author":"C Lebherz","year":"2008","unstructured":"Lebherz C, Maguire A, Tang W, Bennett J, Wilson JM. Novel AAV serotypes for improved ocular gene transfer. J Gene Med. 2008;10(4):375\u201382. https:\/\/doi.org\/10.1002\/jgm.1126.","journal-title":"J Gene Med"},{"issue":"13","key":"2237_CR139","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1038\/s41433-024-03065-6","volume":"38","author":"F Testa","year":"2024","unstructured":"Testa F, et al. Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice. Eye. 2024;38(13):2504\u201315. https:\/\/doi.org\/10.1038\/s41433-024-03065-6.","journal-title":"Eye"},{"issue":"12","key":"2237_CR140","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.ymthe.2018.10.017","volume":"26","author":"R Salzman","year":"2018","unstructured":"Salzman R, et al. Addressing the value of gene therapy and enhancing patient access to transformative treatments. Mol Ther. 2018;26(12):2717\u201326. https:\/\/doi.org\/10.1016\/j.ymthe.2018.10.017.","journal-title":"Mol Ther"},{"issue":"2","key":"2237_CR141","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.biotechadv.2017.12.013","volume":"36","author":"RP Harrison","year":"2018","unstructured":"Harrison RP, Ruck S, Rafiq QA, Medcalf N. Decentralised manufacturing of cell and gene therapy products: learning from other healthcare sectors. Biotechnol Adv. 2018;36(2):345\u201357. https:\/\/doi.org\/10.1016\/j.biotechadv.2017.12.013.","journal-title":"Biotechnol Adv"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02237-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02237-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02237-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:34:08Z","timestamp":1763044448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02237-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":141,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2237"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02237-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated to update the typo error in the funding note.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study does not involve human participants, human data or human tissue.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable. This study does not involve individual data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication and to participate"}},{"value":"The authors (Kai-Yang Chen, Hoi-Chun Chan, and Chi-Ming Chan) declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"K.-Y. C. contributed to conceptualization, methodology, software, investigation, validation, writing the original draft, visualization, and formal analysis. H.-C. C. was responsible for conceptualization, methodology, and software. C.-M. C. handled methodology, investigation, validation, supervision, and project administration. All authors reviewed\u00a0the\u00a0manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}